Haemato-oncology Clinical Forum. 20 th June 2013

Transcription

1 Haemato-oncology Clinical Forum 20 th June 2013

2 Welcome Dr Majid Kazmi, LCA Haemato-oncology Pathway Group Chair

3 Purpose of today Provide an update on progress of the LCA to date Identify priorities for haemato-oncology across the LCA Explore data and metrics for haemato-oncology Identify people to become involved in pathway group, task & finish and sub groups Encourage networking and shared learning across the LCA

4 Agenda Progress of the LCA Implications of Commissioning for haematological cancers Priorities in Haematological Cancers across the LCA Metrics Proposed model for pathway group Round table discussions Next steps and close Shelley Dolan Kate Haire Majid Kazmi Steve Scott Majid Kazmi All Majid Kazmi

5 Progress of the London Cancer Alliance Dr Shelley Dolan, LCA Associate Clinical Director

6 London Cancer Alliance (LCA) The LCA was established in 2011 as the integrated cancer system across west and south London. We work collaboratively with 17 NHS provider organisations, including two academic health science centres, and the voluntary sector. We provide comprehensive, integrated cancer patient pathways and services within formal, governed structures to drive improvements in patient cancer outcomes and experience for the population we serve.

7 The 2 Integrated Cancer Systems: London Cancer & London Cancer Alliance

8 Milestones for LCA Cancer Case for Change published December 2009; Model of Care published August 2010; Two Integrated Cancer Systems approved for London December Core Planning Group, 2012 Interim Clinical Board, Members Board, 6 first wave Pathway Groups established: Lung, Breast, Oseophago-Gastric, Survivorship, Palliative Care, Acute Oncology M.O.U. signed by Boards of 17 Providers 2012 Appointment of Independent Chairs Dec 2012 Appointment of Clinical Director and Associate Clinical Director Formal appointment of all Pathway Chairs Final Pathway Groups established Including haemato-oncology

9 London Cancer Alliance Working with all 17 NHS provider organisations, the LCA has developed the following governance framework:

10 Governance Appointments December 2012 Dr Neil Goodwin - Chair Members Board Dame Gill Morgan - Chair Clinical Board Prof Arnie Purushotham - Clinical Director Dr Shelley Dolan - Associate Clinical Director

11 Pathway Groups Tumour Specific Lung Breast Colorectal Brain CNS Oesophago-Gastric Children and Young People Gynaecology Oncology Haemato-oncology Head and Neck HPB Skin Urology

12 Cross Cutting Groups Early Diagnosis Acute Oncology Palliative and end of life care Patient experience and information Radiotherapy Survivorship Mental Health & Psychology Chemotherapy closer to home and medicines optimisation

13 The LCA vision To provide equitable, world-class cancer care, health outcomes and patient experience for Londoners, delivered through comprehensive and seamless pathways, based on national and international standards, research and evidence

14 LCA - Objectives Promote prevention/early detection by supporting GPs and influencing public health messages Ensure equitable access to excellent clinical care through integrated pathways across primary, secondary, tertiary, community and third sectors Provide local services where possible and centralised services where necessary Collaborate in world class research and innovation in cancer care Raise the profile and improve clinical education across the system

15 Questions

16 NHS Structure and commissioning arrangments Dr Kate Haire

17 NHS April 2013 onwards

18 Transforming Cancer Services: governance structure NHS London Clinical Senate NHS England- London Regional Office Specialised Commissioning CSUs CCTs Clinical Commissioning Groups Transforming Cancer Services Health & Wellbeing Boards Cancer Clinical Leadership Advisory Group London Cancer Commissioning Board CPE :Public Health England AHSN NW & South Joint Development Group (S & W) Joint Development Group (N & E) :NHS England Specialised Commissioning London NHS Cancer QI (NCAT) Programme CONFIDENTIA L London Cancer Alliance ICS London Cancer ICS

19 Commissioning of cancer pathway Referral from primary care Rapid access clinics Prevention Early Detection LA CCGs NHS England Primary care contracts Specialised services 3 rd Sector Assessment and diagnosis common cancers Assessment and diagnosis rare cancers Acute Oncology Service Treatment Surgery: rare cancers BMT Chemotherapy Radiotherapy Stereotactic Radiation therapy Surgery: common cancers Fertility services Survivorship Relapse Palliative care

20 NHS England: Specialised Services NHS England: strategic planning through service specific Clinical Reference Groups (CRGs): 74 CRGs are clustered around the five national Programmes of Care Interim service specifications (final versions in the autumn) Key CRGs: Chemotherapy Radiotherapy Blood & Marrow Transplantation PET-CT Specialised Cancer (Chairs of site-specific CRGs) Derogation Work programme priorities : Service specification CQUIN Quality metrics CRG information:

21 NHS England: Primary Care Primary Care Contracts Local Area Teams (LATs) Core services CCGs as groups of GP practices will have a duty to support the NHS England in improving the quality of primary medical care Enhanced services QOF: Cancer (NICE) The contractor establishes and maintains a register of all cancer patients defined as a register of patients with a diagnosis of cancer excluding non-melanotic skin cancers diagnosed on or after 1 April 2003 The percentage of patients with cancer diagnosed within the preceding 15 months who have a review recorded as occurring within 3 months of the practice receiving confirmation of the diagnosis No new indicators for cancer in the QOF consultation for 2014/15

22 London Clinical Commissioning Groups Support through Commissioning Support Units / Cancer Commissioning teams CCG Council / Cancer Commissioning Board pan-london approach?

23 CCG Outcomes Indicator 1.4: Under 75 mortality rate from cancer: Age/sex standardised rate per 100,000 population Darker shades = higher mortality rate (80-180/100,000)

24 Public Health England (PHE) 4 Regional Offices London Office is a region and centre; 3 patches Functions PH Intelligence including cancer registries Health Improvement Team: obesity, exercise, mental health, smoking, alcohol National Cancer Screening Programme Healthcare public health (specialised commissioning) Health Protection(>60% of workforce) Reducing inequalities PH Outcomes Framework: <75 years mortality rate cancer Cancer diagnosed at stage 1&2 Cancer screening coverage

25 Transforming Cancer Services: Commissioning Priorities Reducing variation in cancer services Breast Lung Colorectal Brain Implementing an early detection strategy Improving patient experience: HNA, treatment plans and summaries Delivering care closer to home - palliative care Implementing a chemotherapy strategy (national work) Implementing a radiotherapy strategy (national work)

26 LCA Strategic Priorities Key issues for pathway groups Clinical service plan to deliver Model of Care Transforming Cancer Services Programme Priorities (site specific and cross-cutting) Research and innovation Matrix working with cross-cutting pathway groups Resources: prioritisation of pathway group work programme, CIs Flexibility to take account of emerging priorities (CRGs / national policy) Feeding into CRG to influence national work Work of London Cancer Integrated Cancer System

27 Questions

28 Priorities in Haematological Cancers and BMT across the LCA Dr Majid Kazmi, LCA Haemato-oncology Pathway Group Chair

29 LCA Objectives Promote prevention/early detection by supporting GPs and influencing public health messages Ensure equitable access to excellent clinical care through integrated pathways across primary, secondary, tertiary, community and third sectors Provide local services where possible and centralised services where necessary Collaborate in world class research and innovation in cancer care raise the quality and profile of clinical education across the system Improve patient experience with reference to the national cancer patient survey

30 Pathway Group Specific Objectives Model of Care Assess haematological cancers and HPCT recommendations in the Model of Care Implement plans to deliver where appropriate Pan LCA Approach Amalgamate existing network guidelines Standardisation of MDT working Cross cutting pathways Other priorities

31 Model of Care Key Recommendations (I) Providers of care for haematological cancers in London should adopt all the recommendations made in the BSH in Levels of Care - Need to establish compliance with Levels of Care - Baseline audit - Action plan to address any issues

32 Model of Care Key Recommendations (II) Commissioners should further consolidate HPCT services to five providers each undertaking a minimum of 100 new cases a year - Baseline current LCA provision - Review Model of Care recommendation - National Service Specifications

33 Pan LCA Approach (I) Amalgamation of three network guidelines into an LCA wide guideline Lymphoid disorders plasma cell disorders myeloid disorders including myeloproliferative disorders/ myelodysplasia For each disease: - Chemo regimens - Best practice pathways - Regimen specific consent forms - Priorities for implementation - Resource implications

34 Pan LCA Approach (II) Standardisation of MDT working across the LCA Consistent approach across the LCA Consistency of cases presented at MDTs Standard information on referral forms Minimal data on MDT proforma Attendance requirements for clinicians at MDTs Ensuring compliance with peer review

35 LCA Cross Cutting Priorities Cross cutting group Early Diagnosis Chemotherapy Patient Experience Survivorship Palliative Care Haematological Cancers and BMT - Specialist integrated haematological malignancy diagnostic service - Chemotherapy closer to home - Review findings from National Cancer Patient Experience Survey - Fertility issues for BMT - Place of death for patients with haematological cancers

36 Other Priorities Quarterly Forums Audit Metrics Education, Research & Development Improving access to clinical trials Opportunities for collaboration Teenagers and Young Adults Peer review compliance Other priorities we may have missed

37 Challenges for the Pathway Group Delivering all of the above Implementation of LCA clinical guidelines once agreed Effective communication with wider clinical community

38 Questions

39 Pathway Group Proposed Model Dr Majid Kazmi, LCA Haemato-oncology Pathway Group Chair

40 Pathway Group proposed membership Pathway Group Chair SE London lead SW London lead NW London lead SWL outgoing TWG chair Nursing representative Pharmacy representative Pathology representative Radiology representative Survivorship and Late Effects TYA lead Chemotherapy representative Specialist Palliative Care lead Education, Research & Development lead LCA Project Manager

41 Task and Finish Groups Transplantation (Model of Care) Amalgamation of Guidelines Standardisation of MDT working Metrics Integrated diagnostics and specialised diagnostics Education, Research and Development (ongoing subgroup)

42 Pathway Group Specific Priorities Overview of all priorities Model of care recommendations Audit against Levels of Haematological Care BSH Peer review Cross cutting priorities Coordination with task and finish groups

43 Reporting and Communication

44 Questions

45 Round Table Discussion Two key points from each group

46 Areas for discussion Challenges facing delivery of haemato-oncology services Solutions How can we demonstrate these will improve outcomes for patients Data and metrics audit Pathway Group Any gaps in pathway group structure? Clinical representatives on task & finish and sub groups? Communication between Pathway Group and MDTs

47 Round Table Feedback Two key points from each group

48 Next steps and close Dr Majid Kazmi, LCA Haemato-oncology Pathway Chair

49 Next Steps and Close Confirm Pathway Group Members Confirm membership of task & finish groups First Pathway Group meeting (Sept) Task & finish groups underway Draft clinical guidelines Next quarterly forum Thursday 10 th October Review position of guidelines amalgamation Agree LCA set of Haemato-oncology metrics Ongoing effective communication between MDTs and Pathway Group

50 What would we like from you? Own the agenda and implementation Identify any other priorities Work effectively through the Haemato-oncology Pathway Group Deliver LCA programme across & through MDTs Focus on priorities Build strong relationships across LCA, share ideas Be proactive and responsive Be supportive, collegiate, influence & reason Please call Dr Majid Kazmi, members of the Haemato-oncology Pathway Group (once established) or LCA Programme team to discuss issues anytime you need to Speak and act on behalf of the London Cancer Alliance

51 And finally Thank you for your contributions today Confirm if you are interested in pathway group/ task & finish groups Please complete feedback forms to inform future forums Any questions please contact: Michelle Bull (020)

52 Thank you Presentations will be available on the LCA website: